Expert Interview
A Second Look: Discussing avutometinib from Verastem and its phase 1/2 trials RAMP 201 (Part A and B) & 203 trials (combo with KRAS for LGSOC or low grade serous ovarian cancer)
Ticker(s): VSTMInstitution: Yale Cancer Center
- Professor, Co-Chief, and Clinical Research Team Leader in Gynecologic Oncology at Yale Cancer Center.
- Treats 50 patients with with BRCA1/2, PALB2 or RAD51C/D mutations.
- Research focuses on immunotherapy for ovarian, cervical and endometrial carcinomas refractory to standard treatment modalities; development of therapeutic vaccines against Human Papillomavirus (HPV) infected genital tumors, and the use of monoclonal antibodies against chemotherapy resistant gynecologic malignancies.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
